CTCAE 6 Pro vs IOTOX Algorithm

CTCAE 6 Pro helps you review and take notes on CTCAE content with ease. It is not intended for diagnosis, clinical decisions, or treatment planning. Standard Features: • Quick CTCAE Access: Browse CTCAE 6.0 content with ease • Unlimited Flags: Bookmark AEs without limits • Search with Highlighting: Easily spot keywords in context • Local Data Storage: Keep your data secure and private on your device Premium Features (Subscription Users): • Version Comparison (5.0 ⇄ 6.0) • Smart Notes: Organize CTCAE entries chronologically, use hashtags, and more • Spreadsheet to App: Turn your spreadsheet into a custom list app—no coding required • Easy Backups: Export to XLSX or CSV for flexibility • Optimized Printing & Sharing: Export HTML files for instant viewing on any desktop or laptop, with easy letter-size printing • Timeline Management: Track and log AEs on a day-by-day basis

Immunotherapies have become essential in treating advanced malignancies. However, immunotherapies can attack healthy cells, leading to toxicities or side effects. To address how to best treat patients with these toxicities, the Internal Medicine division has collaborated with the Cancer Medicine division, as well as other divisions at MD Anderson, to create the Immuno-Oncology Toxicity (IOTOX) Leaders Group. ​​​​​​​ Clinical management algorithms depict best practices for evaluating, diagnosing, and treating specific conditions that arise during the course of cancer treatment. These algorithms are not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine a patient's care.